Andi Dyla currently serves as an Associate in Group M&A at Roche since October 2024. Prior to this role, Andi worked at Roivant Sciences from February 2019 to June 2024, starting as an Analyst in Business Development and Investments and later advancing to an Associate in Corporate Development, focusing on partnering and M&A activities. Andi's earlier experience includes teaching in primary and secondary schools for Kanton Basel-Stadt from November 2014 to October 2018 and completing an internship in the Business Engineering team at SIX in 2016. Academic qualifications include a Master of Arts in Accounting and Finance from the University of St.Gallen, participation in Harvard Medical School's HMX Certificate Program with a focus on immunology and pharmacology, and a Bachelor of Arts in Business Economics also from the University of St.Gallen.
This person is not in the org chart
This person is not in any teams
This person is not in any offices